Clinical trials: Obese Adults
Muscle Wasting, Obesity & Overweight
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more…
- Conditions
- Muscle Wasting, Obesity & Overweight, Obesity
- Trial name
- OBA (NCT07411378)
- Testing
- BIO101, Semaglutide
- Volunteers
- 164 people
- Sponsor
- Biophytis
Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver…
- Trial name
- NCT07441252
- Testing
- Maridebart cafraglutide
- Where
- 23 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen
Obesity
The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE
Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator pepper, belongs to the Zingiberaceae family, which is native to West Africa.
- Trial name
- NCT03894137
- Testing
- Grains of Paradise (Aframomum Melegueta)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Plexus Worldwide
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Obesity
MagDI Diversion Feasibility Study
The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI Bio-fragmentable) for creation of a side-by-side…
- Trial name
- NCT05692518
- Testing
- MAGNET System, DI Bio-fragmentable
- Where
- Georgia
- Volunteers
- 15 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- AURORA-1 (NCT07743463)
- Testing
- ASC30 tablets A1
- Where
- 122 sites in United States, Canada and 5 more
- Volunteers
- 3,003 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
This is a randomized, placebo-controlled, double-blind, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of ASC36 Tablets for Oral Use in Adult…
- Trial name
- NCT07893106
- Testing
- ASC36 tablets, for oral use
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Phase 1 Study of NGM313 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
- Trial name
- NCT02708576
- Testing
- NGM313
- Where
- Australia
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Overweight, Obesity
PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals
This is a six month lifestyle management study to compare the effects of iWell; a dynamic online interactive technology to a self-directed program in overweight or obese individuals.
- Trial name
- NCT01325376
- Testing
- Technology assisted health behavior, Self directed
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- SK Telecom Americas, Inc.
Overweight, Obesity
A Study of HS-20094 in Chinese Adults With Overweight or Obesity
The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.
- Trial name
- NCT06839664
- Testing
- HS-20094 injection
- Where
- China
- Volunteers
- 604 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Obesity
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
- Trial name
- NCT00479492
- Testing
- CP-866,087
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Pfizer
Healthy
Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)
The purpose of this study is to examine the rate and extent of absorption of three oral formulations of ertugliflozin (PF 04971729, MK-8835) administered in lean to obese healthy volunteers.
- Trial name
- NCT01114568
- Testing
- Ertugliflozin 10 mg tablet, Ertugliflozin OC Fast, Ertugliflozin OC Slow
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overweight and Obesity
Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage
The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes…
- Trial name
- NCT04433273
- Testing
- Electrical vestibular nerve stimulation
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Obesity, Type 2 Diabetes
Magnetic Jejuno-Ileal Diversion Study ("MJI Study")
The purpose of this clinical research study is to evaluate the feasibility/performance, safety and initial efficacy of the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System (Magnet System, DI Biofragmentable…
- Trial name
- NCT06232746
- Testing
- Magnet System, DI Biofragmentable
- Where
- Czechia
- Volunteers
- 9 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 1 Diabetes, Obesity
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
- Conditions
- Type 1 Diabetes, Obesity, Overweight
- Trial name
- SURPASS-T1D-2 (NCT06962280)
- Testing
- Tirzepatide
- Where
- 79 sites in United States, Argentina and 8 more
- Volunteers
- 465 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06567327
- Testing
- Danuglipron, Atorvastatin, Rosuvastatin
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Trial name
- ENLIGHTEN-1 (NCT07321886)
- Testing
- Eloralintide
- Where
- 158 sites in United States, Argentina and 13 more
- Volunteers
- 1,980 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
- Trial name
- NCT06174779
- Testing
- HM11260C
- Where
- South Korea
- Volunteers
- 448 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity & Overweight
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
- Trial name
- NCT07890870
- Testing
- IBIO-610
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.